Frankreich

RUBIS: Disclosure of the total number of voting rights and of the number of shares on 05/29/2020

Friday, May 29, 2020 - 7:07pm

This document is a translation of the original French document and is provided for information purposes only.

Key Points: 
  • This document is a translation of the original French document and is provided for information purposes only.
  • In all matters of interpretation of information, views or opinions expressed therein, the original French version takes precedence over this translation.
  • It is divided into:
    100,483,061(1) ordinary shares with a nominal value of 1.25 and 100,483,061 voting rights;
    5,428 preferred shares with a nominal value of 1.25 and no voting rights.
  • Including 400,000 new shares issued on 19 January 2018, 250,000 new shares issued on 19 February 2018, 300,000 new shares issued on 27 March 2018, 250,000 new shares issued on 20 April 2018 and 400,000 new shares issued on 21 March 2019, in the framework of the equity line set up with Crdit Agricole CIB and Socit Gnrale on July 21, 2017.

ALD: Update on the share buyback program

Thursday, May 28, 2020 - 9:03pm

ALD is a global leader in mobility solutions providing full service leasing and fleet management services across 42 countries to a client base of large corporates, SMEs, professionals and private individuals.

Key Points: 
  • ALD is a global leader in mobility solutions providing full service leasing and fleet management services across 42 countries to a client base of large corporates, SMEs, professionals and private individuals.
  • A leader in its industry, ALD places sustainable mobility at the heart of its strategy, delivering innovative mobility solutions and technology-enabled services to its clients, helping them focus on their everyday business.
  • With 6,500 employees around the globe, ALD manages 1.78million vehicles (at end-March 2020).
  • ALD is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: ALD) and is included in the SBF120 index.

ALD: Description of the share buyback programme

Thursday, May 28, 2020 - 8:03pm

Maximum amount allocated to the share buyback programme, maximum number and characteristics of the securities, maximum purchase price

Key Points: 
  • Maximum amount allocated to the share buyback programme, maximum number and characteristics of the securities, maximum purchase price
    The resolution approved at the General Meeting provides that ALD can purchase its ordinary shares for an amount of up to 5% of the share capital at the date of making these purchases, it being specified that the maximum number of shares held after these purchases may not at any time exceed 10% of share capital.
  • As at 18 May 2020, without taking into account the shares already held, a theoretical maximum number of 40,410,364 shares could be purchased.
  • The maximum purchase price was set at EUR 28.6 per share.
  • The authorisation limits the amount of funds allocated to the programme to EUR 600 million.

Voltalia SA: Voltalia wins a 30-year concession for the largest solar plant in West Balkans

Thursday, May 28, 2020 - 6:02pm

Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces it won a concession contract for a 140-megawatt solar plant in Karavasta, Albania.

Key Points: 
  • Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces it won a concession contract for a 140-megawatt solar plant in Karavasta, Albania.
  • Albania's Ministry of Infrastructure and Energy announced that it awarded Voltalia a 30-year concession contract.
  • With a capacity of 140 megawatts, the Karavasta project will be Voltalia's second biggest solar plant worldwide.
  • "We are very pleased to consolidate our presence in Europe with the largest solar plant in the West Balkan region.

DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'

Monday, May 25, 2020 - 5:01pm

PARIS, France May 25, 2020 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today the publication of its 2020 Universal Registration Document (Document d'Enregistrement Universel 2020), filed with the French Financial Market Authorities, Autorit des Marchs Financiers (AMF), on May 25, 2020.

Key Points: 
  • PARIS, France May 25, 2020 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today the publication of its 2020 Universal Registration Document (Document d'Enregistrement Universel 2020), filed with the French Financial Market Authorities, Autorit des Marchs Financiers (AMF), on May 25, 2020.
  • The Registration Document includes the 2019 Annual Report, the corporate governance report prepared by the Board of Directors, and the conclusions of the statutory auditors.
  • An English translation of the universal registration document will be available on June 30, 2020 at the latest.
  • Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.